NO2451435T3 - - Google Patents

Info

Publication number
NO2451435T3
NO2451435T3 NO10797770A NO10797770A NO2451435T3 NO 2451435 T3 NO2451435 T3 NO 2451435T3 NO 10797770 A NO10797770 A NO 10797770A NO 10797770 A NO10797770 A NO 10797770A NO 2451435 T3 NO2451435 T3 NO 2451435T3
Authority
NO
Norway
Application number
NO10797770A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43427659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2451435(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2451435T3 publication Critical patent/NO2451435T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B17/00—Sulfur; Compounds thereof
    • C01B17/64—Thiosulfates; Dithionites; Polythionates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/80—Compositional purity
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/23—Carbon containing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO10797770A 2009-07-08 2010-07-07 NO2451435T3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22399309P 2009-07-08 2009-07-08
PCT/US2010/041182 WO2011005841A1 (en) 2009-07-08 2010-07-07 Sodium thiosulfate-containing pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO2451435T3 true NO2451435T3 (no) 2018-03-31

Family

ID=43427659

Family Applications (1)

Application Number Title Priority Date Filing Date
NO10797770A NO2451435T3 (no) 2009-07-08 2010-07-07

Country Status (12)

Country Link
US (14) US8496973B2 (no)
EP (2) EP2451435B2 (no)
JP (9) JP5905387B2 (no)
AU (1) AU2010270605B2 (no)
CA (1) CA2767168C (no)
DK (1) DK2451435T4 (no)
ES (1) ES2655883T5 (no)
HU (1) HUE035519T2 (no)
NO (1) NO2451435T3 (no)
PL (1) PL2451435T5 (no)
PT (1) PT2451435T (no)
WO (1) WO2011005841A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AU2010270605B2 (en) * 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
WO2013104099A1 (en) * 2012-01-09 2013-07-18 General Electric Company Methods of stabilizing total organic carbon (toc) levels in non-acidified standards for toc analyzers at room temperature
JP2015516407A (ja) * 2012-05-10 2015-06-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 異所性石灰化の治療のためのチオ硫酸ナトリウム
FR2992861B1 (fr) * 2012-07-09 2014-10-17 Probionov Utilisation de thiosulfate pour potentialiser l'effet anti-pathogene des lactobacilles
WO2014116097A2 (es) * 2013-01-28 2014-07-31 Nuevas Alternativas Naturales Thermafat, S.A.P.I. De C.V. Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox
WO2014165057A1 (en) * 2013-03-12 2014-10-09 Sichtnik Laszlo Compositions and methods for treating infectious disease
CN104749304A (zh) * 2013-12-26 2015-07-01 上海宝钢化工有限公司 一种测定脱硫溶液中氰离子与硫离子浓度的方法
US9539305B1 (en) * 2014-03-14 2017-01-10 Fleurir Abx Llc Pristinamycin compositions, LpxC compositions, their improvements, and combinations thereof
CN104071759B (zh) * 2014-06-13 2016-07-06 安徽佑骏商品混凝土有限公司 一种硫代硫酸钠的制备方法
WO2018085748A1 (en) * 2016-11-04 2018-05-11 Robinson Deanne Mraz Methods and compositions for degrading calcium phosphate and for treating calcification disorders
IL302827B2 (en) 2017-03-08 2024-10-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
KR102706379B1 (ko) 2017-03-08 2024-09-19 호프 메디칼 엔터프라이즈스, 인크, 디비에이, 호프파마수으티칼즈 아질산나트륨의 투석중 용도
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
CN112020359A (zh) 2018-02-09 2020-12-01 分贝治疗公司 含有抗铂化学保护剂的高渗药物组合物
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN112805014A (zh) 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠的调配物
CN109678598B (zh) * 2018-09-29 2021-05-18 江西省农业科学院土壤肥料与资源环境研究所 一种土壤修复肥料及其制备方法
US11166981B2 (en) * 2019-04-03 2021-11-09 National Jewish Health Methods and compositions for treating chlorine-gas induced lung injury
CN110146605A (zh) * 2019-04-19 2019-08-20 南通联亚药业有限公司 一种测定格列吡嗪原料药及其缓释片中特定基因毒性杂质的分析方法
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
WO2020243536A1 (en) * 2019-05-31 2020-12-03 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
FR3099051A1 (fr) * 2019-07-25 2021-01-29 Laboratoires Grimberg Composition pour pulvérisation nasale ou buccale contenant du soufre
CN110426473B (zh) * 2019-08-09 2022-03-15 广西壮族自治区亚热带作物研究所（广西亚热带农产品加工研究所） 一种同时测定酱腌菜中三种防腐剂的方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
US20220288110A1 (en) * 2021-02-22 2022-09-15 Arterez, Inc. Drug treatment and biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
EP4212149A1 (en) 2022-01-18 2023-07-19 Rijksuniversiteit Groningen Oral dosage forms of acid-labile salt and methods and uses related thereto
CN115444857B (zh) * 2022-08-30 2023-08-01 安徽丰原药业股份有限公司 一种氰化物解毒剂注射液的制备方法
WO2024092228A2 (en) * 2022-10-28 2024-05-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Localized delivery of sodium thiosulfate nanoparticles to mitigate arterial calcification
CN116062708B (zh) * 2022-12-02 2024-09-17 东南大学 一种硫代硫酸钠的合成方法
US20240277758A1 (en) * 2022-12-28 2024-08-22 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Use of sodium thiosulfate for the treatment of sulfur mustard exposure

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1488829A (en) * 1923-04-18 1924-04-01 Jessup & Mnoore Paper Co Process of making cooking liquors
US2032699A (en) * 1932-07-23 1936-03-03 Solvay Process Co Process for the production of sodium nitrite
US2023699A (en) 1934-06-11 1935-12-10 Albert P Robinson Vehicle ventilating means
GB500489A (en) * 1936-08-07 1939-02-09 Ig Farbenindustrie Ag Improvements in or relating to the manufacture of water-soluble hyposulphites
US2475616A (en) * 1945-02-09 1949-07-12 Harold E Ingraham Thiosulfate salts
US2763531A (en) * 1952-11-29 1956-09-18 Eastman Kodak Co Manufacture of sodium thiosulphate from sodium sulfite and sulfur in presence of cationic surface active organic bromides
NL203871A (no) 1955-02-09 1900-01-01
US2933377A (en) * 1956-08-01 1960-04-19 Du Pont Process for making non-caking and free-flowing sodium nitrite
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
JPS4838557B1 (no) * 1970-12-24 1973-11-17
JPS4733199U (no) 1971-05-15 1972-12-13
JPS4838557A (no) 1971-09-22 1973-06-06
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5131115B2 (no) * 1973-06-05 1976-09-04
US4162187A (en) * 1974-05-09 1979-07-24 The Mead Corporation Process for production of sodium thiosulfate and sodium hydroxide
US3965247A (en) * 1975-06-20 1976-06-22 Allied Chemical Corporation Recovery of sodium nitrite from by-product process liquors containing sodium chloride
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4105754A (en) * 1977-10-25 1978-08-08 Allied Chemical Corporation Production of high purity calcium thiosulfate
US4543190A (en) 1980-05-08 1985-09-24 Modar, Inc. Processing methods for the oxidation of organics in supercritical water
US4292311A (en) 1980-12-23 1981-09-29 Sarnoff Stanley J Cyanide antidote
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
USH1126H (en) 1991-11-12 1993-01-05 The United States Of America As Represented By The Secretary Of The Navy Treatment of sodium nitrite-containing boiler wastewater
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH05286712A (ja) * 1992-04-08 1993-11-02 Asahi Chem Ind Co Ltd 硫化アルカリ含有溶液の酸化方法
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5405533A (en) 1993-04-07 1995-04-11 General Atomics Heat transfer via dense gas in a fluid circulation system
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5387398A (en) 1993-12-03 1995-02-07 Aerojet General Corporation Supercritical water oxidation reactor with wall conduits for boundary flow control
US6056883A (en) 1994-06-07 2000-05-02 Abitibi Consolidated Inc. Method and apparatus to remove inorganic scale from a supercritical water oxidation reactor
US5501799A (en) 1994-06-07 1996-03-26 Abitibi-Price, Inc. Method to remove inorganic scale from a supercritical water oxidation reactor
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5804066A (en) 1996-02-08 1998-09-08 Aerojet-General Corporation Injector for SCWO reactor
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
BR9711585A (pt) 1996-10-01 2000-01-18 Cima Labs Inc Composição de microcápsula, com sabor mascarado, de um remédio solúvel em água, formulação farmacêutica para administrar um remédio, e, processo para disfarçar o sabor de um remédio.
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
EP0938672A1 (en) * 1996-11-18 1999-09-01 Tekmar Company Liquid sample carbon analyzer
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DK0946169T3 (da) 1996-12-20 2003-04-22 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6054057A (en) 1997-09-26 2000-04-25 General Atomics Downflow hydrothermal treatment
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6251354B1 (en) * 1999-04-02 2001-06-26 General Electric Co. Process for recovering sodium nitrite
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6238568B1 (en) 1999-05-06 2001-05-29 General Atomics Hydrothermal processing with phosphate additive
BR0110403A (pt) 2000-04-26 2004-02-25 Univ Oregon Health Sciences Administração de um composto quimioprotetor baseado em tiol
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
KR100331952B1 (ko) 2000-11-23 2002-04-09 최수일 다목적 고기능성 알칼리 용액 조성물 및 그 제조방법과 비특이 면역증강제로서의 용도
US6576185B2 (en) 2000-12-28 2003-06-10 General Atomics System and method for hydrothermal reactions-three layer liner
US6709602B2 (en) 2001-04-23 2004-03-23 General Atomics Process for hydrothermal treatment of materials
US6519926B2 (en) 2001-05-01 2003-02-18 General Atomics Hydrothermal conversion and separation
JP4863589B2 (ja) * 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US6773581B2 (en) 2001-10-18 2004-08-10 General Atomics System and method for solids transport in hydrothermal processes
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US6855306B2 (en) * 2002-09-26 2005-02-15 General Chemical Performance Products Llc Process for the recovery of sodium nitrite
CA2502148A1 (en) * 2002-10-16 2005-02-17 Board Of Regents, The University Of Texas System Methods and compositions for increasing the efficacy of biologically-active ingredients
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
JP5564158B2 (ja) 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 亜硝酸塩によって特定の心臓血管状態を処置する方法
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
AU2004296174A1 (en) * 2003-12-15 2005-06-23 Nitricare Hb Device and method for administering therapeutic agents
JP4315831B2 (ja) 2004-02-17 2009-08-19 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
JP2006143590A (ja) * 2004-10-21 2006-06-08 Rohto Pharmaceut Co Ltd 粘膜適用組成物
JP4838557B2 (ja) 2005-09-12 2011-12-14 キヤノン株式会社 ズームレンズ及びそれを有する撮像装置
RU2372923C2 (ru) * 2007-08-27 2009-11-20 Государственное учреждение Научно-исследовательский институт экспериментальной медицины Российской Академии медицинских наук (ГУ НИИЭМ РАМН) Средство, обладающее гиполипидемической и антиатеросклеротической активностью
US8568793B2 (en) * 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
AU2010270605B2 (en) * 2009-07-08 2014-07-31 Hope Medical Enterprises, Inc. Dba Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
KR101601393B1 (ko) 2014-02-20 2016-03-09 현대자동차주식회사 차량용 비상 버튼

Also Published As

Publication number Publication date
HUE035519T2 (en) 2018-05-02
PL2451435T3 (pl) 2018-04-30
ES2655883T3 (es) 2018-02-22
JP6182622B2 (ja) 2017-08-16
JP2012532824A (ja) 2012-12-20
JP6852136B2 (ja) 2021-03-31
US8496973B2 (en) 2013-07-30
US20110008467A1 (en) 2011-01-13
EP2451435A4 (en) 2013-05-29
JP2023015121A (ja) 2023-01-31
US9579345B2 (en) 2017-02-28
US20220063999A1 (en) 2022-03-03
JP2016153360A (ja) 2016-08-25
JP2021107318A (ja) 2021-07-29
US20130287676A1 (en) 2013-10-31
US20240101422A1 (en) 2024-03-28
US9144580B2 (en) 2015-09-29
US20190100432A1 (en) 2019-04-04
JP6598965B2 (ja) 2019-10-30
US9585912B2 (en) 2017-03-07
US20160367594A1 (en) 2016-12-22
AU2010270605B2 (en) 2014-07-31
JP2020011992A (ja) 2020-01-23
US9345724B2 (en) 2016-05-24
JP2017165758A (ja) 2017-09-21
DK2451435T3 (en) 2018-01-15
JP2016106110A (ja) 2016-06-16
EP2451435B2 (en) 2021-12-01
US10479686B2 (en) 2019-11-19
US20140205558A1 (en) 2014-07-24
US10479687B2 (en) 2019-11-19
US20140302179A1 (en) 2014-10-09
US20160235782A1 (en) 2016-08-18
US11753301B2 (en) 2023-09-12
CA2767168A1 (en) 2011-01-13
DK2451435T4 (da) 2022-02-28
US11142456B2 (en) 2021-10-12
JP6438071B2 (ja) 2018-12-12
US8715746B2 (en) 2014-05-06
PL2451435T5 (pl) 2022-03-14
US20170129779A1 (en) 2017-05-11
US10723623B2 (en) 2020-07-28
US9944524B2 (en) 2018-04-17
WO2011005841A1 (en) 2011-01-13
EP2451435A1 (en) 2012-05-16
JP5905387B2 (ja) 2016-04-20
JP7166377B2 (ja) 2022-11-07
AU2010270605A1 (en) 2012-02-02
US11753300B2 (en) 2023-09-12
ES2655883T5 (es) 2022-04-18
EP3213756A1 (en) 2017-09-06
EP2451435B1 (en) 2017-11-01
PT2451435T (pt) 2018-01-15
JP6166393B2 (ja) 2017-07-19
JP2019048852A (ja) 2019-03-28
US20200317520A1 (en) 2020-10-08
JP2024037998A (ja) 2024-03-19
US20230183067A1 (en) 2023-06-15
US20190144276A1 (en) 2019-05-16
JP7408753B2 (ja) 2024-01-05
US20180194628A1 (en) 2018-07-12
CA2767168C (en) 2019-04-09

Similar Documents

Publication Publication Date Title
BR112012008267A2 (no)
BR112012003062A2 (no)
BR112012008195A2 (no)
BR112012000607A2 (no)
BRPI0925311A2 (no)
BR122021004633A2 (no)
BR112012003080A2 (no)
BR112012000665A2 (no)
BR112012003853A2 (no)
BR112012009797A2 (no)
NO2451435T3 (no)
BR112012009446A2 (no)
BR112012009703A2 (no)
BR112012007656A2 (no)
BR112012001263A2 (no)
BR122019005883A2 (no)
BR112012002627A2 (no)
BR112012000159A2 (no)
BR112012007654A2 (no)
BR112012007672A2 (no)
BR112012005951A2 (no)
BR112012000255A2 (no)
BR112012009404A2 (no)
BR112012000156A2 (no)
BR112012007671A2 (no)